Howard J. Jacob to Deliver Daniel T. O’Connor Memorial Lecture February 23

Dr. Howard J. Jacob will present the Daniel T. O’Connor 2nd Annual Memorial Lecture on Thursday, February 23, 2017, at UC San Diego School of Medicine. His topic is “From Hypertension to Genomic Medicine.”

Dr. Jacob’s lecture will take place in the Leichtag Auditorium (Room 107), with a reception immediately following on the patio.

Dr. Jacob is Executive Vice President for Medical Genomics, Chief Medical Genomics Officer, and Faculty Investigator at HudsonAlpha Institute for Biotechnology. His UC San Diego hosts are Bruce A. Hamilton, PhD, and Nicholas J. Schork, PhD.

Dr. Hamilton is Professor, Cellular and Molecular Medicine, Department of Medicine; Director, Genetics Training Program; and Associate Director, Institute for Genomic Medicine. Dr. Schork is UC San Diego Adjunct Professor, Psychiatry, Family and Preventive Medicine and Director of Human Biology, J. Craig Venter Institute.

The lecture is presented in conjunction with the UC San Diego CTRI Seminar Series and the Genetics, Bioinformatics and Systems Biology Colloquium Series.

Altman Clinical and Translational Research Institute Building Opens March 4

Stunning structure will house array of scientists and centers dedicated to speeding basic research into new treatments and therapies —

Rising above Interstate 5 on the east campus of University of California, San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI), a five-sided polygon of glass, steel and grooved concrete, officially opens its doors March 4 in a ribbon-cutting ceremony.

“The building is an architectural marvel, but more important is what it represents and the work that will go on inside,” said UC San Diego Chancellor Pradeep K. Khosla. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary Firestein

The director of the Clinical and Translational Research Institute at UC San Diego is Gary S. Firestein, MD, Professor of Medicine and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.

CTRI opened in 2010 as a part of the national Clinical and Translational Science Award consortium through a five-year, $37.2 million grant from the National Center for Advancing Translational Science of the National Institutes of Health. CTRI received a $52 million renewal grant last year.

More about the activities of the CTRI

 

Live Long and Measure: Quest to Create Real-World Tricorder

XPRIZE teams will test Star Trek-inspired medical devices at UC San Diego —

Seeking to boldly go where medical science has not gone before, the Clinical and Translational Research Institute (CTRI) at the University of California, San Diego has been named the official testing site for the $10 million Qualcomm Tricorder XPRIZE, a global competition sponsored by the Qualcomm Foundation to develop a consumer-friendly, mobile device capable of diagnosing and interpreting 15 physiological conditions and capturing vital health metrics.

The XPRIZE competition is inspired by the tricorder medical device that debuted in the original 1966 Star Trek TV show and was frequently featured in subsequent series and movies. …Read the full story from the UC San Diego Newsroom


Dr. Gary FiresteinGary S. Firestein, MD, is director of the CTRI and dean and associate vice chancellor of translational medicine at UC San Diego.

He is professor of medicine in the Division of Rheumatology, Allergy and Immunology and served as division chief from 1998 until he stepped down in 2010 to focus on his growing responsibilities as dean of translational medicine and director of the CTRI for UC San Diego Health Sciences.

Hannah Carter Receives NIH Early Independence Award

CTRI Helps Launch Career of Bioengineer Hannah Carter

November 22, 2013 – With support from UC San Diego’s Clinical and Translational Research Institute (CTRI), bioengineer Hannah Carter, PhD, received the highly prestigious NIH Early Independence Award and recently began began her transition to a junior faculty position at UC San Diego.

Presently she is acquiring a research team and computational resources to delve into her project: Network approaches to identify cancer drivers from high-dimensional tumor data. … Read the full story from CTRI News & Events


Hannah Carter, PhDHannah Carter, PhD, is assistant professor of medicine in the Division of Medical Genetics. Her project is Network Approaches to Identify Cancer Drivers from High-Dimensional Tumor Data.

She is now recruiting postdoctoral fellows for her project, which is funded for five years.

Carter Laboratory website

 

UC Medical Campus Consortium Named Designated Center to Translate Innovations into Improved Health

A consortium of the five University of California medical campuses at UC San Diego, UC Davis, UC Irvine, UCLA and UC San Francisco has been designated a Center for Accelerated Innovations by the National Heart, Lung and Blood Institute (NHLBI). The designation, among the first of its kind from NHLBI, recognizes the University of California’s potential to translate its leading-edge discoveries into innovative products that benefit patients. … Read the full story from the UCSD Newsroom


Dr. Gary FiresteinGary S. Firestein, MD, chair of the UC BRAID consortium that will oversee the new UC Center for Accelerated Innovations, is dean and associate vice chancellor of translational medicine at UC San Diego Health Sciences

He led UC San Diego’s successful effort to win a Clinical and Translational Science Award in 2010 and is the founding director of the UC San Diego Clinical and Translational Research Institute.

Firestein is professor of medicine and former chief of the Division of Rheumatology, Allergy & Immunology at UC San Diego. He served as division chief from 1998 until he stepped down in 2010 to devote full time to his activities as dean of translational medicine.

In 2011, philanthropists Lisa and Steve Altman made a major gift to the planned Clinical and Translational Research building on the La Jolla campus of UC San Diego Health System. Construction started in early 2013 and the building, named the Altman Clinical and Translational Research Institute, is scheduled to open in 2016.

UC San Diego Health System Video: The Altman Clinical and Translational Research Institute

More Information:

UC San Diego Health Sciences Receives Gift for Translational Research Building

$10 million from San Diego residents Steve and Lisa Altman will support the Clinical and Translational Research Institute

UC San Diego Health Sciences today announced that San Diego philanthropists and long-time residents Steve and Lisa Altman have pledged $10 million to the planned Clinical and Translational Research Institute (CTRI) building… Read the full story from the UCSD Newsroom

Dr. Gary Firestein, director of the Clinical and Translational Research Institute, is dean and associate vice chancellor of Translational Medicine for UC San Diego Health Sciences. He is Professor of Medicine in the Division of Rheumatology, Allergy and Immunology.

CTRI Receives $37.2 Million Clinical and Translational Science Award

A 5-year, $37.2 million grant award for the Clinical and Translational Research Institute (CTRI) is the subject of the UCSD Newsroom story, “UC San Diego Receives Major Clinical and Translational Science Award.”

Dr. Gary Firestein, Director of the CTRI, is principal investigator of the project. Dr. Firestein is Dean of Translational Medicine for UC San Diego Health Sciences and Professor of Medicine in the Division of Rheumatology, Allergy and Immunology.

Dr. Gary Firestein Steps Down as Chief of Rheumatology, Allergy and Immunology; Dr. Robert Terkeltaub Named Interim Chief

Dr. Gary Firestein

Dr. Gary Firestein

Dr. Gary Firestein will step down as Chief of the Rheumatology, Allergy and Immunology division as of July 1, announced Dr. Ken Kaushansky, Helen M. Ranney Distinguished Professor and outgoing Chair of the Department of Medicine.

Dr. Firestein, who has been chief of the division since 1998, is making the move because of the increasing demands of his leadership responsibilities as Dean of Translational Medicine and Director of the Clinical and Translational Research Institute (CTRI) for UCSD Health Sciences.

“During the last 12 years, the division grew dramatically in both accomplishments and international visibility. This is due entirely to the incredibly creative faculty, our outstanding trainees, and the dedicated staff,” said Dr. Firestein.

“I want to express my thanks to Dr. Firestein for being such an outstanding division leader for the past 12 years,” said Dr. Kaushansky. “Under Gary’s leadership, the division has continued to grow and prosper in all three of its missions: research, education, and clinical care.

“The division has gone from unranked to a consistent top-20 ranking in the ‘America’s Best Hospitals’ list from U.S.News & World Report,” he said. “Its research portfolio has grown to be generally among the largest in the department.”

“Gary has also overseen the creation and expansion of the Center for Innovative Therapy as a model for translational medicine and helped bring in supporting program project grants,” Dr. Kaushansky said.

These include the NIH-funded Specialized Centers of Research program on rheumatoid arthritis, the Rheumatic Diseases Core Center grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and a new NIAMS Ruth L. Kirschstein T32 Training Grant to support research training in rheumatic diseases.

“Gary has also recruited a number of very successful research-oriented faculty into the Rheumatology and Allergy/Immunology sections,” Dr. Kaushansky said. “The division’s clinical mission has expanded to include a novel multidisciplinary clinic with the Department of Orthopaedics.

Dr. Robert Terkeltaub

Dr. Robert Terkeltaub

Dr. Robert A. Terkeltaub, Professor of Medicine, will serve as Interim Chief. For most of the last decade, Dr. Terkeltaub has served as Associate Director of the division and Director of the Rheumatology Training Program.

He has been Chief of the Rheumatology Section at the VA San Diego Healthcare System since 1985.

“I’m grateful to Dr. Robert Terkeltaub for agreeing to serve in the interim role,” said Dr. Kaushansky. “I know he will carry on the rich tradition of the division.”

“Dr. Terkeltaub is an outstanding physician-scientist who has played an integral role in the division’s success. We are truly grateful that he agreed to take on this new responsibility,” said Dr. Firestein.

“I look forward to helping the division through the transition period and into the future,” Dr. Terkeltaub said.

“We are very proud of our faculty and their accomplishments,” he said. “We want to ensure that the clinical programs remain strong and the clinical, translational, and basic research from our very accomplished faculty members grows in breadth, quality, and scope.”

Another goal, he said, is to increase the division’s interaction with other Department of Medicine divisions, including the three newest – Geriatrics, Global Public Health, and Biomedical Informatics.

About Dr. Terkeltaub

Dr. Terkeltaub received his M.D. degree and completed his internship, residency, and fellowship at McGill University in Montreal, Canada. From 1981 to 1984, he was a postdoctoral fellow in the laboratory of Dr. Mark Ginsberg at The Scripps Research Institute in La Jolla.

He spent the following year as a research associate at The Scripps Research Institute before he joined the UCSD faculty as Assistant Professor of Medicine in the Division of Rheumatology, Allergy and Immunology and Chief of the Rheumatology Section at the VA San Diego Healthcare System.

Dr. Terkeltaub has served on numerous study sections for the National Institutes of Health, the American Heart Association, the Arthritis National Research Foundation, and other organizations. He is currently Associate Editor of the journal Arthritis & Rheumatism.

As an investigator, Dr. Terkeltaub studies the interfaces of inflammation with skeletal and vascular biology, focusing on arthritis and vascular diseases, including infantile artery calcification, gout, and osteoarthritis. At the VA and UCSD, his lab discovered the molecular etiology of generalized artery calcification of infancy, and has done seminal research on innate immunity in gout, and on cartilage innate immunity and chondrocyte hypertrophy in osteoarthritis.

About Dr. Firestein

Dr. Gary Firestein first joined the UCSD Department of Medicine faculty in 1988 as Assistant Professor of Medicine in the Division of Rheumatology, Allergy and Immunology.

He spent 1992 through 1996 as Senior Director of Immunology for Gensia, Inc, and returned to UCSD as Associate Professor of Medicine in 1996. He was promoted to Professor of Medicine in 1998, when he was also appointed division chief.

On a personal note, Dr. Kaushansky said, “Gary was the only person I knew at UCSD when I started interviewing for the position here. We collaborated on a couple of papers back in our formative days.”

Those days were in the late 1980s, when Dr. Kaushansky was Assistant Professor in the Division of Hematology at the University of Washington and the younger Dr. Firestein was Assistant Professor in the Rheumatology, Allergy and Immunology division here at UCSD.

The two papers reported some of Dr. Firestein’s earliest work, with his mentor and then-division chief Dr. Nathan Zvaifler, on the presence of pro-inflammatory mediators in the synovial fluid of rheumatoid arthritis patients.

In the following years, Dr. Firestein’s basic science studies would open the way for the development of anti-cytokine agents as the first broadly effective treatments for rheumatoid arthritis.

Dr. Firestein was founding director of the UCSD Clinical Investigation Institute, a responsibility that has evolved into his current role as Director of the Clinical and Translational Research Institute.

He was appointed Dean of Translational Medicine for UCSD Health Sciences in 2008.

2009 Funding Offered in New UCSD K12 Grant Program for Junior Faculty Investigators

Applications are now being accepted for a new, institutionally-funded grant program for junior faculty investigators at UCSD.

Offered through UCSD’s Clinical and Translational Research Institute (CTRI), the K12 grants are the institutional equivalent of a National Institutes of Health K23 or K08 mentored career development award.

Applications must be received January 9, 2009, for funding to begin July 1, 2009. All applicants will be notified by March 2, 2009.


Get application form and instructions


Eligible candidates include UCSD instructors or assistant professors in any academic series and fellows or postdocs who are completing their training. Applicants must secure their home departments’ approval before applying.

Each applicant and his/her home department must commit to the applicant’s 75% level of research effort through the project period.

In this first annual competition for the K12 funding, up to two investigators will receive support for up to 3 years from the Dean’s Office and from their home departments. The Dean’s Office and the home department each will grant $50,000 toward salary and benefits.

Funded investigators will be offered early didactic opportunities and in-depth formal and informal research mentoring through the UCSD CREST program.

UCSD’s CTRI K12 Program is directed by Joel E. Dimsdale, M.D., Distinguished Professor of Psychiatry. Dilip Jeste, M.D., Estelle and Edgar Levi Chair in Aging and Distinguished Professor of Psychiatry and Neurosciences, is Director of the CTRI Education and Community Alliances Division.

More Information